Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes.
Authors:
- Salah Y AbbasiSASalah Y Abbasi
- Hani El TaaniHTHani El Taani
- Adnan SaadASAdnan Saad
- Ahmed BadheebAhmed Badheeb
- Ala' AddasiAAAla' Addasi
- 1 July 2011
- journal article
- Vol. 4 (4) , 122-7
Abstract
WE REPORT THE EPIDEMIOLOGIC FEATURES AND THE TREATMENT EXPERIENCE OF ADVANCED GASTRIC CANCER (GC) AT KING HUSSEIN CANCER CENTER (KHCC) IN JORDAN, AND WE RETROSPECTIVELY COMPARE OUTCOMES OF TWO DIFFERENT REGIMENS: DCF (docetaxel/cisplatin/5-fluorouracil) vs. ECF (epirubicin/cisplatin/5-fluorouracil). Charts of 162 patients with inoperable GC treated between January 2004 and December 2008 were reviewed. A total 143 patients received chemotherapy (ECF = 113; DCF = 30). Choice of regimen was changed from ECF to DCF on January 2008 according to KHCC guidelines. The median patient age was 59 years, with a male:female ratio of 1.8:1. Lymph nodes (67.9%) and liver (49.4%) were the most common sites of metastasis. Primary disease site was stomach in 78.4%, gastroesophageal junction in 16.7%, lower esophagus in 4.9%. Poorly differentiated histology was predominant (46.9%). Anemia (53.7%), pain (48.1%), and reflux (44.4%) were the most common presenting symptoms. Helicobacter pylori infection was present in 79%. Average time between initial symptom and diagnosis was 6.0 months. The overall response rate (ORR) was 59.3% with DCF and 32.6% with ECF (P = .01). Time to tumor progression (TTP) was 6.9 months with DCF and 5.9 months with ECF (P = .005). Median survival was 11.0 months with DCF and 10.2 months with ECF (P = .17). Some epidemiologic features of GC in Jordan mimic those of high-risk areas. Our outcomes of chemotherapy are comparable to internationally reported data and suggest superiority of DCF over ECF in terms of ORR and TTP.Keywords
This publication has 27 references indexed in Scilit:
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Prevalence of Helicobacter pylori in Northern Jordan. Endoscopy based studySaudi Medical Journal, 2001
- Gastric cancer and Helicobacter pylori : a combined analysis of 12 case control studies nested within prospective cohortsGut, 2001
- Gastric carcinoma at Tikur Anbessa Hospital, Addis Ababa.2000
- Estimates of the worldwide incidence of 25 major cancers in 1990International Journal of Cancer, 1999
- [Incidence of gastric cancer in the 02 health area of Castellon].1996
- Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancerAnnals of Oncology, 1995
- Helicobacter pylori Infection in Rural Settlements (Kibbutzim) in IsraelInternational Journal of Epidemiology, 1995
- Epidemiology of intestinal and diffuse types of gastric carcinoma a time-trend study in finland with comparison between studies from high- and low-risk areasCancer, 1993